



For Less Invasive Surfactant Administration (LISA) in preterm and term neonates¹

An overview of the most important questions/facts about Neofact®:

1. How was Neofact® developed?

Neofact® was developed by a neonatologist at the neonatology centres of Tübingen University and Olga Hospital Stuttgart, Germany. The goal was to develop a simple, less stressful procedure for applying surfactant without having to use Magill forceps. The Neofact® applicator that resulted helps stabilise the catheter, making it easier to manoeuvre, and offers an unobstructed view. The 3.5 Fr catheter can also be used at any gestational age.

2. How many sizes of Neofact® are available?

Neofact® is available in one size. The catheter is 55 cm long and has an outer diameter of 3.5 Fr. Neofact® can be used for all gestational ages.

3. Why is the angle of the tip important?

The 50° atraumatic, angled tip enables precise positioning in front of the glottis – without the aid of Magill forceps.

4. Why is it the Luer connection?

Luer is a standardised system for connecting syringes and infusion sets in the medical field.

5. Why does Neofact® have a black tip?

The 1 cm black tip of the catheter contrasts well against the mucosa, facilitating a visible control of the insertion depth.

6. What are the advantages of the design?

The Neofact® applicator helps stabilise the catheter, making it easier to manoeuvre, and offers an unobstructed view. The user also benefits from ergonomic handling.

7. Why is doing away with Magill forceps advantageous?

The mucosa and vocal cords of preterm infants are very soft and prone to injuries. Magill forceps are bulky and not easy to use. There is a risk of pinching the respiratory mucosa with the forceps which could cause bleeding or injuries. The atraumatic, angled tip is designed to avoid injuries to the vocal cords.





8. How should the surfactant be injected through Neofact®?

The physician should refer to the instructions for use of the surfactant concerning the modalities of administration. It is usually administered very slowly while monitoring the patient's tolerance. If needed, air can be injected to expel the remaining surfactant.

9. Can Neofact® be used with other surfactants?

Yes, Neofact® was developed so that it can be combined with other surfactants. However, clinical studies have only been carried out with the natural bovine surfactant Alveofact®.²

10. Is any current study data available on Neofact?

The study „Clinical evaluation of an application aid for less-invasive surfactant administration (LISA)“ is an open-access study that can be downloaded using these links:

<https://pubmed.ncbi.nlm.nih.gov/33023914/>

<https://fn.bmj.com/content/106/2/211>

In addition, an instructional video on the use of Neofact has been posted as online supplementary material.

11. Is Neofact® sterile?

Yes, Neofact® is a sterile product.

12. What is the shelf-life of Neofact®?

The shelf-life of Neofact® is 2 years.

13. Is it possible to re-use Neofact®?

No, Neofact® is intended for single use only.

14. Is the product Neofact® latex free?

Yes, Neofact® is latex free.

15. How should Neofact® be stored?

Neofact® must be stored at room temperature. It must be kept away from direct sunlight and moisture. After use, dispose of the product according to the provisions of the clinic or local regulations.

16. What class of CE mark does Neofact® have?

Neofact® has a class IIa CE mark.

17. Where is Neofact® manufactured?

Neofact® is manufactured in Germany.



Lyomark Pharma GmbH
Keltenring 17 · 82041 Oberhaching
Tel.: 089/45 08 08 78-0
info@lyomark.com · www.lyomark.com

CE 0124

¹ Alveofact SMPC (as of September 2020)

² Maiwald CA et al. Clinical evaluation of an application aid for less-invasive surfactant administration (LISA). Arch Dis Child Fetal Neonatal Ed.2021 Mar;106(2):211-214.